Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$78.61 USD

78.61
3,963,653

-0.63 (-0.80%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $78.62 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nalak Das headshot

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare

by Zacks Equity Research

Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.

Bryan Hayes headshot

Medical Devices ETF Hits 52-Week High: Stocks to Watch

by Bryan Hayes

Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.

Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.

Zacks Equity Research

Here's How Much a $1000 Investment in Edwards Lifesciences Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Edwards Lifesciences (EW) Up 2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth

by Zacks Equity Research

With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.

Zacks Equity Research

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

Zacks Equity Research

If You Invested $1000 in Edwards Lifesciences a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat, Operating Margin Up

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter revenues suffer due to unfavorable currency movement. However, the company???s transformational plans continue to benefit its operating income.

Zacks Equity Research

Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Here's Why You Should Add Masimo (MASI) to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Zacks Equity Research

Edwards (EW) Gains From Balanced Core Growth and New Launches

by Zacks Equity Research

Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.

Mark Vickery headshot

Top Research Reports for Alibaba, General Electric & Honeywell

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), General Electric Company (GE) and Honeywell International Inc. (HON).

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics

by Zacks Equity Research

Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.

Urmimala Biswas headshot

3 Medtech Stocks Likely to Top Estimates This Earnings Season

by Urmimala Biswas

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

Zacks Equity Research

Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip

by Zacks Equity Research

Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.

Zacks Equity Research

Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Edwards Lifesciences (EW) Q4 Earnings Match Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 2.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

by Zacks Equity Research

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Zacks Equity Research

ITGR or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Stay Ahead of the Game With Edwards Lifesciences (EW) Q4 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.